These findings suggest that adiposity contributes to TNBC progression via the activation of the LIF/LIFR pathway, and LIFR inhibition with EC359 represents a promising therapeutic approach for obesity-associated TNBC. The gene discussed is LIF; the disease is obesity due to melanocortin 4 receptor deficiency.